ArticleThe Biochemical journal2002
Inhibitor specificity of recombinant and endogenous caspase-9.
Article in The Biochemical journal, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 36 citations in OpenAlex.
- Caspase selective reagents for diagnosing apoptotic mechanisms.Cell death and differentiation · 2019Article
- Vaccinia Virus Encodes a Novel Inhibitor of Apoptosis That Associates with the Apoptosome.Journal of virology · 2017Article
- Intrinsic-mediated caspase activation is essential for cardiomyocyte hypertrophy.Proceedings of the National Academy of Sciences of the United States of America · 2013Article
- Regulation of Immune Responses by Spontaneous and T cell-mediated Dendritic Cell Death.Journal of clinical & cellular immunology · 2011Article
- Programmed cell death of dendritic cells in immune regulation.Immunological reviews · 2010Review
- An improved in vitro and in vivo Sindbis virus expression system through host and virus engineering.Virus research · 2009Article
- Caspase-8 cleaves histone deacetylase 7 and abolishes its transcription repressor function.The Journal of biological chemistry · 2008Article
- Mathematical modeling of the formation of apoptosome in intrinsic pathway of apoptosis.Systems and synthetic biology · 2008Article
- Dominant-negative FADD rescues the in vivo fitness of a cytomegalovirus lacking an antiapoptotic viral gene.Journal of virology · 2008Article
- Requirement of Apaf-1 for mitochondrial events and the cleavage or activation of all procaspases during genotoxic stress-induced apoptosis.The Biochemical journal · 2007Article
- Involvement of caspase-9 in the inhibition of necrosis of RAW 264 cells infected with Mycobacterium tuberculosis.Infection and immunity · 2007Article
- Article
- Human inhibitor of apoptosis proteins: why XIAP is the black sheep of the family.EMBO reports · 2006Review
- Induction of apoptosis limits cytomegalovirus cross-species infection.The EMBO journal · 2006Article
- Caspase-9 and effector caspases have sequential and distinct effects on mitochondria.Oncogene · 2005Article
- The protein structures that shape caspase activity, specificity, activation and inhibition.The Biochemical journal · 2004Review
- Processed caspase-2 can induce mitochondria-mediated apoptosis independently of its enzymatic activity.EMBO reports · 2004Article
- The crucial role of caspase-9 in the disease progression of a transgenic ALS mouse model.The EMBO journal · 2003Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Apoptosis triggered through the intrinsic pathway by radiation and anti-neoplastic drugs is initiated by the activation of caspase-9. To elucidate control mechanisms in this pathway we used a range of synthetic and natural reagents. The inhibitory potency of acetyl-Asp-Glu-Val-Asp-aldehyde ('Ac-DEVD-CHO'), benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone ('Z-VAD-FMK') and the endogenous caspase inhibitor X-chromosome-linked inhibitor of apoptosis protein ('XIAP') against recombinant caspase-9 were predictive of the efficacy of these compounds in a cell-free system. However, the viral proteins CrmA and p35, although potent inhibitors of recombinant caspase-9, had almost no ability to block caspase-9 in this system. These findings were also mirrored in cell expression studies. We hypothesize that the viral inhibitors CrmA and p35 are excluded from reacting productively with the natural form of active caspase-9 in vivo, making the potency of inhibitors highly context-dependent. This is supported by survival data from a mouse model of apoptosis driven by Sindbis virus expressing either p35 or a catalytic mutant of caspase-9. These results consolidate previous findings that CrmA is a potent inhibitor of caspase-9 in vitro, yet fails to block caspase-9-mediated cell death.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.